Crinetics Pharmaceuticals, Inc. (CRNX) 10-Year Financial Performance & Capital Metrics

CRNX •

HealthcareBiotechnologyCommercial Rare Disease Biopharma

AboutCrinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Show more

Revenue $5M +421.7%
EBITDA -$517M -53.8%
Net Income -$465M -55.9%
EPS (Diluted) -4.95 -34.1%
Gross Margin 80.15% -19.9%
EBITDA Margin -9534.48% +70.5%
Operating Margin -9534.48% +70.8%
Net Margin -8585.18% +70.1%
ROE -40.17% -25.4%
ROIC -37.79% -22.5%
Debt/Equity 0.05 +25.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 138.0%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Shares diluted 16.4% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y137.98%

3Y4.59%

TTM421.66%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-55.93%

EPS CAGR

10Y-

5Y-

3Y-

TTM-33.42%

ROCE

10Y Avg-46.07%

5Y Avg-43.83%

3Y Avg-41.95%

Latest-42.78%

Peer Comparison

Commercial Rare Disease Biopharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CORTCorcept Therapeutics Incorporated	3.78B	35.70	43.54	12.79%	13.01%	15.3%	3.75%	0.01
BMRNBioMarin Pharmaceutical Inc.	11.86B	61.73	34.29		10.83%	5.73%	6.11%	0.10
VRTXVertex Pharmaceuticals Incorporated	126.19B	496.83	32.43	8.9%	31.35%	21.22%	2.53%	0.20
CPRXCatalyst Pharmaceuticals, Inc.	2.83B	23.08	13.74	19.78%	36.39%	22.46%	7.38%	0.00
HRMYHarmony Biosciences Holdings, Inc.	1.65B	28.54	10.53	21.51%	18.27%	18.24%	21.12%	0.02
PTCTPTC Therapeutics, Inc.	5.45B	68.19	8.76	114.51%	42.25%
BCRXBioCryst Pharmaceuticals, Inc.	1.86B	8.75	7.23	94.1%	30.16%		18.63%
RAREUltragenyx Pharmaceutical Inc.	2.26B	23.39	-3.72	29.01%	-91.95%	-35.88%		0.15

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	589K	2.04M	2.43M	1.19M	71K	1.08M	4.74M	4.01M	1.04M	5.42M
Revenue Growth %	-	247.2%	18.73%	-50.86%	-94.05%	1418.31%	339.42%	-15.28%	-74.11%	421.66%
Cost of Goods Sold+	5.1M	9.23M	24.48M	1.11M	57M	0	0	0	0	1.08M
COGS % of Revenue	865.87%	451.49%	1008.2%	93.29%	80278.87%	-	-	-	-	19.85%
Gross Profit+	-4.51M	-7.19M	-22.05M	80K	-56.93M	1.08M	4.74M	4.01M	1.04M	4.34M
Gross Margin %	-765.87%	-351.49%	-908.2%	6.71%	-80178.87%	100%	100%	100%	100%	80.15%
Gross Profit Growth %	-	-59.34%	-206.78%	100.36%	-71258.75%	101.89%	339.42%	-15.28%	-74.11%	318.09%
Operating Expenses+	6.04M	9.13M	28.71M	53.83M	18.03M	108.78M	172.62M	226.62M	339.89M	523.39M
OpEx % of Revenue	1026.15%	446.31%	1182.45%	4512.32%	25388.73%	10090.91%	3644.06%	5647.17%	32713.47%	9656.62%
Selling, General & Admin	1.53M	1.94M	6.66M	13.52M	18.03M	24.52M	42.39M	58.09M	99.74M	191.33M
SG&A % of Revenue	260.27%	94.82%	274.26%	1133.19%	25388.73%	2275.05%	894.95%	1447.65%	9599.33%	3530.09%
Research & Development	5.1M	9.23M	24.48M	41.51M	57.6M	84.25M	130.22M	168.53M	240.16M	332.06M
R&D % of Revenue	865.87%	451.49%	1008.2%	3479.13%	81123.94%	7815.86%	2749.1%	4199.53%	23114.15%	6126.53%
Other Operating Expenses	-1K	-48K	1.59M	-1.19M	-57.6M	0	0	0	0	0
Operating Income+	-6.04M	-9.13M	-28.71M	-53.83M	-74.95M	-107.7M	-167.88M	-222.61M	-338.85M	-516.77M
Operating Margin %	-1026.15%	-446.31%	-1182.45%	-4512.32%	-105567.61%	-9990.91%	-3544.06%	-5547.17%	-32613.47%	-9534.48%
Operating Income Growth %	-	-51.01%	-214.56%	-87.5%	-39.23%	-43.69%	-55.88%	-32.6%	-52.22%	-52.5%
EBITDA+	-5.95M	-9M	-28.24M	-52.72M	-74M	-106.78M	-166.9M	-221.51M	-336.07M	-516.77M
EBITDA Margin %	-1010.53%	-440.05%	-1163.06%	-4419.03%	-104232.39%	-9905.38%	-3523.31%	-5519.81%	-32345.43%	-9534.48%
EBITDA Growth %	-	-51.19%	-213.8%	-86.69%	-40.38%	-44.29%	-56.3%	-32.72%	-51.72%	-53.77%
D&A (Non-Cash Add-back)	92K	128K	471K	1.11M	948K	922K	983K	1.1M	2.79M	0
EBIT	-6.01M	-9.15M	-27.11M	-53.83M	-74.95M	-107.7M	-167.88M	-222.61M	-338.85M	0
Net Interest Income+	26K	18K	0	3.46M	991K	157K	4.32M	13.44M	41.44M	0
Interest Income	37K	26K	1.75M	3.46M	991K	157K	4.32M	13.44M	41.44M	51.99M
Interest Expense	11K	8K	0	0	0	0	0	0	0	0
Other Income/Expense	25K	-30K	1.59M	3.41M	1.14M	61K	3.96M	8.08M	40.45M	51.63M
Pretax Income+	-6.02M	-9.16M	-27.11M	-50.42M	-73.81M	-107.64M	-163.92M	-214.53M	-298.41M	-465.14M
Pretax Margin %	-1021.9%	-447.78%	-1116.76%	-4226.49%	-103960.56%	-9985.25%	-3460.38%	-5345.85%	-28720.69%	-8581.86%
Income Tax+	10K	-40K	0	0	0	0	0	0	0	180K
Effective Tax Rate %	100%	100%	100%	98.24%	100%	100%	100%	100%	100%	100.04%
Net Income+	-6.02M	-9.16M	-27.11M	-49.53M	-73.81M	-107.64M	-163.92M	-214.53M	-298.41M	-465.32M
Net Margin %	-1021.9%	-447.78%	-1116.76%	-4152.14%	-103960.56%	-9985.25%	-3460.38%	-5345.85%	-28720.69%	-8585.18%
Net Income Growth %	-	-52.13%	-196.11%	-82.68%	-49.01%	-45.83%	-52.28%	-30.88%	-39.1%	-55.93%
Net Income (Continuing)	-6.02M	-9.16M	-27.11M	-50.42M	-73.81M	-107.64M	-163.92M	-214.53M	-298.41M	-465.32M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.43	-0.66	-2.23	-2.05	-2.42	-2.80	-3.15	-3.69	-3.69	-4.95
EPS Growth %	-	-53.49%	-237.88%	8.07%	-18.05%	-15.7%	-12.5%	-17.14%	0%	-34.15%
EPS (Basic)	-0.43	-0.66	-2.23	-2.05	-2.42	-2.80	-3.15	-3.69	-3.69	-4.95
Diluted Shares Outstanding	13.88M	13.88M	12.14M	24.18M	30.45M	38.44M	51.98M	58.07M	80.78M	94.06M
Basic Shares Outstanding	13.88M	13.88M	12.14M	24.18M	30.45M	38.44M	51.98M	58.07M	80.78M	94.06M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	12.37M	15.16M	166.68M	123.34M	177.49M	344.72M	345.18M	574.15M	1.38B	1.05B
Cash & Short-Term Investments	12.15M	14.19M	163.88M	118.39M	170.88M	333.71M	334.43M	558.55M	1.35B	1.03B
Cash Only	12.15M	14.19M	44.97M	40.33M	93.09M	200.69M	32.67M	54.9M	264.55M	101.54M
Short-Term Investments	0	0	118.9M	78.07M	77.79M	133.01M	301.75M	503.66M	1.09B	926.35M
Accounts Receivable	72K	734K	0	1.38M	1.83M	2.03M	2.42M	9.35M	8.47M	592K
Days Sales Outstanding	44.62	131.01	-	421.6	9.42K	687	186.85	850.51	2.98K	39.87
Inventory	98K	141K	0	0	0	0	0	0	0	2.02M
Days Inventory Outstanding	7.01	5.57	-	-	-	-	-	-	-	685.9
Other Current Assets	43K	0	0	1.09M	1.02M	0	2.54M	1.58M	1.71M	17.84M
Total Non-Current Assets+	234K	433K	4.73M	7.04M	5.95M	6.29M	6.99M	61.2M	59.2M	77.92M
Property, Plant & Equipment	224K	400K	4.23M	6.46M	5.41M	4.72M	4.99M	57.43M	55.58M	54.79M
Fixed Asset Turnover	2.63x	5.11x	0.57x	0.18x	0.01x	0.23x	0.95x	0.07x	0.02x	0.10x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	500K	500K	0	1.01M	1.97M	1.77M	800K	0
Other Non-Current Assets	10K	33K	0	82K	540K	568K	37K	2M	2.83M	23.13M
Total Assets+	12.6M	15.6M	171.41M	130.38M	183.44M	351.01M	352.18M	635.35M	1.43B	1.13B
Asset Turnover	0.05x	0.13x	0.01x	0.01x	0.00x	0.00x	0.01x	0.01x	0.00x	0.00x
Asset Growth %	-	23.8%	998.95%	-23.94%	40.7%	91.35%	0.33%	80.41%	125.79%	-21.49%
Total Current Liabilities+	890K	897K	7.92M	8.34M	10.49M	15.99M	27.72M	43.94M	59.68M	85.07M
Accounts Payable	340K	403K	1.46M	2.7M	3.49M	3.42M	6.88M	6.55M	5.85M	0
Days Payables Outstanding	24.33	15.93	21.71	884.79	22.34	-	-	-	-	-
Short-Term Debt	49K	0	0	724K	0	0	1.05M	4.17M	0	6.49M
Deferred Revenue (Current)	0	0	0	0	0	0	2.24M	2.06M	2.18M	1.24M
Other Current Liabilities	0	0	590K	2.8M	4.9M	7.53M	8.47M	16.65M	10K	77.35M
Current Ratio	13.89x	16.91x	21.03x	14.79x	16.92x	21.55x	12.45x	13.07x	23.04x	12.32x
Quick Ratio	13.78x	16.75x	21.03x	14.79x	16.92x	21.55x	12.45x	13.07x	23.04x	12.30x
Cash Conversion Cycle	27.3	120.65	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	17.91M	29.72M	3.27M	4.9M	4.04M	3.08M	8.13M	52.3M	50.1M	49.1M
Long-Term Debt	163K	0	0	0	0	0	0	0	0	42.05M
Capital Lease Obligations	0	0	0	4.85M	4.01M	3.07M	2.02M	47.55M	44.57M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	17.75M	29.72M	3.27M	49K	23K	2K	0	0	829K	7.05M
Total Liabilities	18.8M	30.62M	11.19M	13.24M	14.53M	19.07M	35.85M	96.25M	109.79M	134.17M
Total Debt+	212K	0	0	5.57M	4.01M	3.07M	3.08M	51.73M	51.72M	48.54M
Net Debt	-11.94M	-14.19M	-44.97M	-34.75M	-89.07M	-197.62M	-29.6M	-3.17M	-212.82M	-52.99M
Debt / Equity	-	-	-	0.05x	0.02x	0.01x	0.01x	0.10x	0.04x	0.05x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-549.45x	-1140.88x	-	-	-	-	-	-	-	-
Total Equity+	-6.2M	-15.02M	-43.38M	117.14M	168.92M	331.94M	316.33M	539.11M	1.32B	992.08M
Equity Growth %	-	-142.13%	-188.78%	370.03%	44.2%	96.51%	-4.7%	70.43%	145.74%	-25.11%
Book Value per Share	-0.45	-1.08	-3.57	4.85	5.55	8.64	6.09	9.28	16.40	10.55
Total Shareholders' Equity	-6.2M	-15.02M	-43.38M	117.14M	168.92M	331.94M	316.33M	539.11M	1.32B	992.08M
Common Stock	1K	1K	24K	210.79M	336.51M	607.58M	759.43M	1.19B	2.28B	2.41B
Retained Earnings	-7.11M	-16.27M	-43.38M	-93.8M	-167.61M	-275.25M	-439.17M	-653.7M	-952.11M	-1.42B
Treasury Stock	0	0	-374.94M	0	0	0	0	0	0	0
Accumulated OCI	-182K	-304K	61K	148K	25K	-382K	-3.93M	977K	963K	1.86M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-5.47M	-9.48M	-19.46M	-46.38M	-62.03M	-88.59M	-115.2M	-166.31M	-225.97M	-377.92M
Operating CF Margin %	-928.35%	-463.52%	-801.44%	-3887.76%	-87361.97%	-8217.81%	-2432.02%	-4144.21%	-21748.8%	-6972.73%
Operating CF Growth %	-	-73.35%	-105.29%	-138.35%	-33.73%	-42.82%	-30.05%	-44.36%	-35.88%	-67.24%
Net Income	-6.02M	-9.16M	-27.11M	-50.42M	-73.81M	-107.64M	-163.92M	-214.53M	-298.41M	-465.32M
Depreciation & Amortization	92K	128K	471K	887K	948K	922K	983K	1.1M	2.79M	3.89M
Stock-Based Compensation	270K	271K	2.32M	6.29M	10.43M	17.35M	28.27M	40.94M	69.39M	91.02M
Deferred Taxes	0	0	0	-1.23M	-227K	422K	0	0	0	0
Other Non-Cash Items	154K	480K	-433K	222K	261K	-739K	850K	-1.86M	-11.37M	-7.52M
Working Capital Changes	189K	-721K	5.3M	-2.13M	376K	1.1M	18.61M	8.04M	11.63M	0
Change in Receivables	0	0	0	0	2.72M	6.29M	10.99M	14.65M	17.54M	-592K
Change in Inventory	0	0	0	0	-2.72M	-6.29M	0	0	0	-2.02M
Change in Payables	300K	47K	7.36M	696K	2.72M	6.29M	0	0	0	0
Cash from Investing+	-190K	-304K	-119.46M	41.67M	217K	-56.48M	-173.98M	-200.41M	-574.82M	173.91M
Capital Expenditures	-190K	-304K	-1.06M	-492K	-186K	-436K	-1.66M	-4.69M	-3.84M	-5.76M
CapEx % of Revenue	32.26%	14.87%	43.62%	41.24%	261.97%	40.45%	34.96%	116.82%	369.97%	106.31%
Acquisitions	0	0	0	-1.23M	-227K	422K	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-118.4M	1.23M	227K	-422K	0	0	0	15.43M
Cash from Financing+	-53K	11.82M	170.2M	67K	114.57M	252.68M	121.96M	388.94M	1.01B	40.61M
Debt Issued (Net)	-48K	-212K	0	0	0	0	0	0	0	0
Equity Issued (Net)	0	1000K	1000K	-59K	1000K	1000K	1000K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-5K	0	0	-59K	0	0	0	0	0	0
Other Financing	-5K	66K	451K	126K	288K	3.14M	4.72M	19.93M	40.39M	40.61M
Net Change in Cash	-5.71M	2.04M	31.28M	-4.65M	52.76M	107.61M	-167.22M	22.22M	209.65M	-163.51M
Free Cash Flow+	-5.66M	-9.78M	-20.52M	-46.87M	-62.21M	-89.02M	-116.86M	-171M	-229.81M	-383.68M
FCF Margin %	-960.61%	-478.39%	-845.06%	-3929%	-87623.94%	-8258.26%	-2466.98%	-4261.03%	-22118.77%	-7079.04%
FCF Growth %	-	-72.91%	-109.73%	-128.45%	-32.73%	-43.1%	-31.27%	-46.32%	-34.4%	-66.95%
FCF per Share	-0.41	-0.70	-1.69	-1.94	-2.04	-2.32	-2.25	-2.94	-2.84	-4.08
FCF Conversion (FCF/Net Income)	0.91x	1.04x	0.72x	0.94x	0.84x	0.82x	0.70x	0.78x	0.76x	0.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-	-	-134.32%	-51.61%	-42.98%	-50.57%	-50.16%	-32.02%	-40.17%
Return on Invested Capital (ROIC)	-	-	-	-	-69.3%	-75.43%	-59.81%	-40.59%	-30.84%	-37.79%
Gross Margin	-765.87%	-351.49%	-908.2%	6.71%	-80178.87%	100%	100%	100%	100%	80.15%
Net Margin	-1021.9%	-447.78%	-1116.76%	-4152.14%	-103960.56%	-9985.25%	-3460.38%	-5345.85%	-28720.69%	-8585.18%
Debt / Equity	-	-	-	0.05x	0.02x	0.01x	0.01x	0.10x	0.04x	0.05x
Interest Coverage	-549.45x	-1140.88x	-	-	-	-	-	-	-	-
FCF Conversion	0.91x	1.04x	0.72x	0.94x	0.84x	0.82x	0.70x	0.78x	0.76x	0.81x
Revenue Growth	-	247.2%	18.73%	-50.86%	-94.05%	1418.31%	339.42%	-15.28%	-74.11%	421.66%

US Stock Screener

...

Crinetics Pharmaceuticals, Inc. (CRNX) 10-Year Financial Performance & Capital Metrics

CRNX •

HealthcareBiotechnologyCommercial Rare Disease Biopharma

Revenue $5M +421.7%
EBITDA -$517M -53.8%
Net Income -$465M -55.9%
EPS (Diluted) -4.95 -34.1%
Gross Margin 80.15% -19.9%
EBITDA Margin -9534.48% +70.5%
Operating Margin -9534.48% +70.8%
Net Margin -8585.18% +70.1%
ROE -40.17% -25.4%
ROIC -37.79% -22.5%
Debt/Equity 0.05 +25.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 138.0%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Shares diluted 16.4% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y137.98%

3Y4.59%

TTM421.66%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-55.93%

EPS CAGR

10Y-

5Y-

3Y-

TTM-33.42%

ROCE

10Y Avg-46.07%

5Y Avg-43.83%

3Y Avg-41.95%

Latest-42.78%

Peer Comparison

Commercial Rare Disease Biopharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CORTCorcept Therapeutics Incorporated	3.78B	35.70	43.54	12.79%	13.01%	15.3%	3.75%	0.01
BMRNBioMarin Pharmaceutical Inc.	11.86B	61.73	34.29		10.83%	5.73%	6.11%	0.10
VRTXVertex Pharmaceuticals Incorporated	126.19B	496.83	32.43	8.9%	31.35%	21.22%	2.53%	0.20
CPRXCatalyst Pharmaceuticals, Inc.	2.83B	23.08	13.74	19.78%	36.39%	22.46%	7.38%	0.00
HRMYHarmony Biosciences Holdings, Inc.	1.65B	28.54	10.53	21.51%	18.27%	18.24%	21.12%	0.02
PTCTPTC Therapeutics, Inc.	5.45B	68.19	8.76	114.51%	42.25%
BCRXBioCryst Pharmaceuticals, Inc.	1.86B	8.75	7.23	94.1%	30.16%		18.63%
RAREUltragenyx Pharmaceutical Inc.	2.26B	23.39	-3.72	29.01%	-91.95%	-35.88%		0.15

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	589K	2.04M	2.43M	1.19M	71K	1.08M	4.74M	4.01M	1.04M	5.42M
Revenue Growth %	-	247.2%	18.73%	-50.86%	-94.05%	1418.31%	339.42%	-15.28%	-74.11%	421.66%
Cost of Goods Sold+	5.1M	9.23M	24.48M	1.11M	57M	0	0	0	0	1.08M
COGS % of Revenue	865.87%	451.49%	1008.2%	93.29%	80278.87%	-	-	-	-	19.85%
Gross Profit+	-4.51M	-7.19M	-22.05M	80K	-56.93M	1.08M	4.74M	4.01M	1.04M	4.34M
Gross Margin %	-765.87%	-351.49%	-908.2%	6.71%	-80178.87%	100%	100%	100%	100%	80.15%
Gross Profit Growth %	-	-59.34%	-206.78%	100.36%	-71258.75%	101.89%	339.42%	-15.28%	-74.11%	318.09%
Operating Expenses+	6.04M	9.13M	28.71M	53.83M	18.03M	108.78M	172.62M	226.62M	339.89M	523.39M
OpEx % of Revenue	1026.15%	446.31%	1182.45%	4512.32%	25388.73%	10090.91%	3644.06%	5647.17%	32713.47%	9656.62%
Selling, General & Admin	1.53M	1.94M	6.66M	13.52M	18.03M	24.52M	42.39M	58.09M	99.74M	191.33M
SG&A % of Revenue	260.27%	94.82%	274.26%	1133.19%	25388.73%	2275.05%	894.95%	1447.65%	9599.33%	3530.09%
Research & Development	5.1M	9.23M	24.48M	41.51M	57.6M	84.25M	130.22M	168.53M	240.16M	332.06M
R&D % of Revenue	865.87%	451.49%	1008.2%	3479.13%	81123.94%	7815.86%	2749.1%	4199.53%	23114.15%	6126.53%
Other Operating Expenses	-1K	-48K	1.59M	-1.19M	-57.6M	0	0	0	0	0
Operating Income+	-6.04M	-9.13M	-28.71M	-53.83M	-74.95M	-107.7M	-167.88M	-222.61M	-338.85M	-516.77M
Operating Margin %	-1026.15%	-446.31%	-1182.45%	-4512.32%	-105567.61%	-9990.91%	-3544.06%	-5547.17%	-32613.47%	-9534.48%
Operating Income Growth %	-	-51.01%	-214.56%	-87.5%	-39.23%	-43.69%	-55.88%	-32.6%	-52.22%	-52.5%
EBITDA+	-5.95M	-9M	-28.24M	-52.72M	-74M	-106.78M	-166.9M	-221.51M	-336.07M	-516.77M
EBITDA Margin %	-1010.53%	-440.05%	-1163.06%	-4419.03%	-104232.39%	-9905.38%	-3523.31%	-5519.81%	-32345.43%	-9534.48%
EBITDA Growth %	-	-51.19%	-213.8%	-86.69%	-40.38%	-44.29%	-56.3%	-32.72%	-51.72%	-53.77%
D&A (Non-Cash Add-back)	92K	128K	471K	1.11M	948K	922K	983K	1.1M	2.79M	0
EBIT	-6.01M	-9.15M	-27.11M	-53.83M	-74.95M	-107.7M	-167.88M	-222.61M	-338.85M	0
Net Interest Income+	26K	18K	0	3.46M	991K	157K	4.32M	13.44M	41.44M	0
Interest Income	37K	26K	1.75M	3.46M	991K	157K	4.32M	13.44M	41.44M	51.99M
Interest Expense	11K	8K	0	0	0	0	0	0	0	0
Other Income/Expense	25K	-30K	1.59M	3.41M	1.14M	61K	3.96M	8.08M	40.45M	51.63M
Pretax Income+	-6.02M	-9.16M	-27.11M	-50.42M	-73.81M	-107.64M	-163.92M	-214.53M	-298.41M	-465.14M
Pretax Margin %	-1021.9%	-447.78%	-1116.76%	-4226.49%	-103960.56%	-9985.25%	-3460.38%	-5345.85%	-28720.69%	-8581.86%
Income Tax+	10K	-40K	0	0	0	0	0	0	0	180K
Effective Tax Rate %	100%	100%	100%	98.24%	100%	100%	100%	100%	100%	100.04%
Net Income+	-6.02M	-9.16M	-27.11M	-49.53M	-73.81M	-107.64M	-163.92M	-214.53M	-298.41M	-465.32M
Net Margin %	-1021.9%	-447.78%	-1116.76%	-4152.14%	-103960.56%	-9985.25%	-3460.38%	-5345.85%	-28720.69%	-8585.18%
Net Income Growth %	-	-52.13%	-196.11%	-82.68%	-49.01%	-45.83%	-52.28%	-30.88%	-39.1%	-55.93%
Net Income (Continuing)	-6.02M	-9.16M	-27.11M	-50.42M	-73.81M	-107.64M	-163.92M	-214.53M	-298.41M	-465.32M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.43	-0.66	-2.23	-2.05	-2.42	-2.80	-3.15	-3.69	-3.69	-4.95
EPS Growth %	-	-53.49%	-237.88%	8.07%	-18.05%	-15.7%	-12.5%	-17.14%	0%	-34.15%
EPS (Basic)	-0.43	-0.66	-2.23	-2.05	-2.42	-2.80	-3.15	-3.69	-3.69	-4.95
Diluted Shares Outstanding	13.88M	13.88M	12.14M	24.18M	30.45M	38.44M	51.98M	58.07M	80.78M	94.06M
Basic Shares Outstanding	13.88M	13.88M	12.14M	24.18M	30.45M	38.44M	51.98M	58.07M	80.78M	94.06M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	12.37M	15.16M	166.68M	123.34M	177.49M	344.72M	345.18M	574.15M	1.38B	1.05B
Cash & Short-Term Investments	12.15M	14.19M	163.88M	118.39M	170.88M	333.71M	334.43M	558.55M	1.35B	1.03B
Cash Only	12.15M	14.19M	44.97M	40.33M	93.09M	200.69M	32.67M	54.9M	264.55M	101.54M
Short-Term Investments	0	0	118.9M	78.07M	77.79M	133.01M	301.75M	503.66M	1.09B	926.35M
Accounts Receivable	72K	734K	0	1.38M	1.83M	2.03M	2.42M	9.35M	8.47M	592K
Days Sales Outstanding	44.62	131.01	-	421.6	9.42K	687	186.85	850.51	2.98K	39.87
Inventory	98K	141K	0	0	0	0	0	0	0	2.02M
Days Inventory Outstanding	7.01	5.57	-	-	-	-	-	-	-	685.9
Other Current Assets	43K	0	0	1.09M	1.02M	0	2.54M	1.58M	1.71M	17.84M
Total Non-Current Assets+	234K	433K	4.73M	7.04M	5.95M	6.29M	6.99M	61.2M	59.2M	77.92M
Property, Plant & Equipment	224K	400K	4.23M	6.46M	5.41M	4.72M	4.99M	57.43M	55.58M	54.79M
Fixed Asset Turnover	2.63x	5.11x	0.57x	0.18x	0.01x	0.23x	0.95x	0.07x	0.02x	0.10x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	500K	500K	0	1.01M	1.97M	1.77M	800K	0
Other Non-Current Assets	10K	33K	0	82K	540K	568K	37K	2M	2.83M	23.13M
Total Assets+	12.6M	15.6M	171.41M	130.38M	183.44M	351.01M	352.18M	635.35M	1.43B	1.13B
Asset Turnover	0.05x	0.13x	0.01x	0.01x	0.00x	0.00x	0.01x	0.01x	0.00x	0.00x
Asset Growth %	-	23.8%	998.95%	-23.94%	40.7%	91.35%	0.33%	80.41%	125.79%	-21.49%
Total Current Liabilities+	890K	897K	7.92M	8.34M	10.49M	15.99M	27.72M	43.94M	59.68M	85.07M
Accounts Payable	340K	403K	1.46M	2.7M	3.49M	3.42M	6.88M	6.55M	5.85M	0
Days Payables Outstanding	24.33	15.93	21.71	884.79	22.34	-	-	-	-	-
Short-Term Debt	49K	0	0	724K	0	0	1.05M	4.17M	0	6.49M
Deferred Revenue (Current)	0	0	0	0	0	0	2.24M	2.06M	2.18M	1.24M
Other Current Liabilities	0	0	590K	2.8M	4.9M	7.53M	8.47M	16.65M	10K	77.35M
Current Ratio	13.89x	16.91x	21.03x	14.79x	16.92x	21.55x	12.45x	13.07x	23.04x	12.32x
Quick Ratio	13.78x	16.75x	21.03x	14.79x	16.92x	21.55x	12.45x	13.07x	23.04x	12.30x
Cash Conversion Cycle	27.3	120.65	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	17.91M	29.72M	3.27M	4.9M	4.04M	3.08M	8.13M	52.3M	50.1M	49.1M
Long-Term Debt	163K	0	0	0	0	0	0	0	0	42.05M
Capital Lease Obligations	0	0	0	4.85M	4.01M	3.07M	2.02M	47.55M	44.57M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	17.75M	29.72M	3.27M	49K	23K	2K	0	0	829K	7.05M
Total Liabilities	18.8M	30.62M	11.19M	13.24M	14.53M	19.07M	35.85M	96.25M	109.79M	134.17M
Total Debt+	212K	0	0	5.57M	4.01M	3.07M	3.08M	51.73M	51.72M	48.54M
Net Debt	-11.94M	-14.19M	-44.97M	-34.75M	-89.07M	-197.62M	-29.6M	-3.17M	-212.82M	-52.99M
Debt / Equity	-	-	-	0.05x	0.02x	0.01x	0.01x	0.10x	0.04x	0.05x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-549.45x	-1140.88x	-	-	-	-	-	-	-	-
Total Equity+	-6.2M	-15.02M	-43.38M	117.14M	168.92M	331.94M	316.33M	539.11M	1.32B	992.08M
Equity Growth %	-	-142.13%	-188.78%	370.03%	44.2%	96.51%	-4.7%	70.43%	145.74%	-25.11%
Book Value per Share	-0.45	-1.08	-3.57	4.85	5.55	8.64	6.09	9.28	16.40	10.55
Total Shareholders' Equity	-6.2M	-15.02M	-43.38M	117.14M	168.92M	331.94M	316.33M	539.11M	1.32B	992.08M
Common Stock	1K	1K	24K	210.79M	336.51M	607.58M	759.43M	1.19B	2.28B	2.41B
Retained Earnings	-7.11M	-16.27M	-43.38M	-93.8M	-167.61M	-275.25M	-439.17M	-653.7M	-952.11M	-1.42B
Treasury Stock	0	0	-374.94M	0	0	0	0	0	0	0
Accumulated OCI	-182K	-304K	61K	148K	25K	-382K	-3.93M	977K	963K	1.86M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-5.47M	-9.48M	-19.46M	-46.38M	-62.03M	-88.59M	-115.2M	-166.31M	-225.97M	-377.92M
Operating CF Margin %	-928.35%	-463.52%	-801.44%	-3887.76%	-87361.97%	-8217.81%	-2432.02%	-4144.21%	-21748.8%	-6972.73%
Operating CF Growth %	-	-73.35%	-105.29%	-138.35%	-33.73%	-42.82%	-30.05%	-44.36%	-35.88%	-67.24%
Net Income	-6.02M	-9.16M	-27.11M	-50.42M	-73.81M	-107.64M	-163.92M	-214.53M	-298.41M	-465.32M
Depreciation & Amortization	92K	128K	471K	887K	948K	922K	983K	1.1M	2.79M	3.89M
Stock-Based Compensation	270K	271K	2.32M	6.29M	10.43M	17.35M	28.27M	40.94M	69.39M	91.02M
Deferred Taxes	0	0	0	-1.23M	-227K	422K	0	0	0	0
Other Non-Cash Items	154K	480K	-433K	222K	261K	-739K	850K	-1.86M	-11.37M	-7.52M
Working Capital Changes	189K	-721K	5.3M	-2.13M	376K	1.1M	18.61M	8.04M	11.63M	0
Change in Receivables	0	0	0	0	2.72M	6.29M	10.99M	14.65M	17.54M	-592K
Change in Inventory	0	0	0	0	-2.72M	-6.29M	0	0	0	-2.02M
Change in Payables	300K	47K	7.36M	696K	2.72M	6.29M	0	0	0	0
Cash from Investing+	-190K	-304K	-119.46M	41.67M	217K	-56.48M	-173.98M	-200.41M	-574.82M	173.91M
Capital Expenditures	-190K	-304K	-1.06M	-492K	-186K	-436K	-1.66M	-4.69M	-3.84M	-5.76M
CapEx % of Revenue	32.26%	14.87%	43.62%	41.24%	261.97%	40.45%	34.96%	116.82%	369.97%	106.31%
Acquisitions	0	0	0	-1.23M	-227K	422K	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-118.4M	1.23M	227K	-422K	0	0	0	15.43M
Cash from Financing+	-53K	11.82M	170.2M	67K	114.57M	252.68M	121.96M	388.94M	1.01B	40.61M
Debt Issued (Net)	-48K	-212K	0	0	0	0	0	0	0	0
Equity Issued (Net)	0	1000K	1000K	-59K	1000K	1000K	1000K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-5K	0	0	-59K	0	0	0	0	0	0
Other Financing	-5K	66K	451K	126K	288K	3.14M	4.72M	19.93M	40.39M	40.61M
Net Change in Cash	-5.71M	2.04M	31.28M	-4.65M	52.76M	107.61M	-167.22M	22.22M	209.65M	-163.51M
Free Cash Flow+	-5.66M	-9.78M	-20.52M	-46.87M	-62.21M	-89.02M	-116.86M	-171M	-229.81M	-383.68M
FCF Margin %	-960.61%	-478.39%	-845.06%	-3929%	-87623.94%	-8258.26%	-2466.98%	-4261.03%	-22118.77%	-7079.04%
FCF Growth %	-	-72.91%	-109.73%	-128.45%	-32.73%	-43.1%	-31.27%	-46.32%	-34.4%	-66.95%
FCF per Share	-0.41	-0.70	-1.69	-1.94	-2.04	-2.32	-2.25	-2.94	-2.84	-4.08
FCF Conversion (FCF/Net Income)	0.91x	1.04x	0.72x	0.94x	0.84x	0.82x	0.70x	0.78x	0.76x	0.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-	-	-134.32%	-51.61%	-42.98%	-50.57%	-50.16%	-32.02%	-40.17%
Return on Invested Capital (ROIC)	-	-	-	-	-69.3%	-75.43%	-59.81%	-40.59%	-30.84%	-37.79%
Gross Margin	-765.87%	-351.49%	-908.2%	6.71%	-80178.87%	100%	100%	100%	100%	80.15%
Net Margin	-1021.9%	-447.78%	-1116.76%	-4152.14%	-103960.56%	-9985.25%	-3460.38%	-5345.85%	-28720.69%	-8585.18%
Debt / Equity	-	-	-	0.05x	0.02x	0.01x	0.01x	0.10x	0.04x	0.05x
Interest Coverage	-549.45x	-1140.88x	-	-	-	-	-	-	-	-
FCF Conversion	0.91x	1.04x	0.72x	0.94x	0.84x	0.82x	0.70x	0.78x	0.76x	0.81x
Revenue Growth	-	247.2%	18.73%	-50.86%	-94.05%	1418.31%	339.42%	-15.28%	-74.11%	421.66%

Crinetics Pharmaceuticals, Inc. (CRNX) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare CRNX vs Peers

vs AGIO

vs VRTX

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Crinetics Pharmaceuticals, Inc. (CRNX) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare CRNX vs Peers

vs AGIO

vs VRTX

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios